Fig. 3From: Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective studyBreakdown of patients included in the study ABC: advanced breast cancer, A/T: anthracycline and/or taxane, HER2: human epidermal growth factor receptor-2 negative, pts: patientsBack to article page